Cenca

Quick links to important sections

Cenca

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cenca

Quick Facts: Cenca

Property Description
Active ingredient Calcium Citrate (tricalcium dicitrate)
Form Oral Solid (Tablet/Capsule) or Oral Solution
Pharmacological class Mineral Supplement, Electrolyte Replacement Agent
General purpose Source of essential mineral for structural and systemic support
Origin Synthetic compound

What is Cenca and What Type of Supplement is it?

Cenca is classified pharmacologically as a Mineral Supplement and an Electrolyte Replacement agent, with its core active component being Calcium Citrate. This substance is an essential nutrient source that plays a vital role in numerous physiological processes. Its composition is typically a single-ingredient product, though it is frequently combined with Vitamin D to optimize absorption. Calcium Citrate is a synthetic compound derived from the essential mineral calcium bound to Citric Acid.


Cenca's Dosage Form and General Purpose

Cenca is manufactured exclusively for oral administration and is typically presented as an oral solid dosage form, such as a Tablet or Capsule, or sometimes as an Oral Solution. The overarching purpose of Cenca is to provide a readily accessible Calcium Source to support the body’s fundamental mineral balance. By replenishing the body’s supply of elemental calcium, this preparation helps maintain the necessary structural integrity of bones and teeth and supports the normal function of muscle and nerve systems. This type of supplement is clinically recognized for preventing or treating low blood calcium, such as in individuals with dietary deficits.


Why Calcium Citrate is Considered a Reliable Source

Calcium Citrate is considered a reliable source because the Citrate salt form offers high bioavailability compared to less soluble calcium salts, such as calcium carbonate. This inherent compositional quality relates to mineral absorption dynamics. The unique structure ensures that a greater proportion of the elemental Calcium can be efficiently absorbed across varying digestive states, making its assimilation less dependent on the presence of high stomach acid levels. This efficiency is critical to the product's ability to consistently contribute to the efficient replenishment of essential mineral supply and support the systemic electrolyte balance.

Regulatory References

  1. Calcium Supplements

What side effects are possible with Cenca?

Adverse reactions (side effects) associated with Cenca are formally documented and categorized by government regulatory authorities based on their frequency, severity, and the body system affected.

Adverse Reaction Scope

The full safety profile includes events identified during clinical trials and post-marketing surveillance, grouped by System Organ Class (SOC).

Frequency Classification

Adverse reactions are classified using standardized frequency bands to indicate how often they occur:

Frequency Category Description (Example Range)
Very Common Occurs in 1 in 10 patients
Common Occurs in 1 in 100 to < 1 in 10 patients
Uncommon Occurs in 1 in 1,000 to < 1 in 100 patients
Rare Occurs in 1 in 10,000 to < 1 in 1,000 patients
Very Rare Occurs in < 1 in 10,000 patients
Not Known Cannot be estimated from available data

Serious Adverse Reactions (SARs)

Regulatory documents define SARs as adverse events that may be life-threatening, result in death, require hospitalization, or result in persistent or significant disability. The documentation of these reactions mandates continuous safety monitoring.

Safety-Related Restrictions

The official labeling includes specific Contraindications, which are conditions where the medicine must not be used due to high or unacceptable risk. Special Warnings and Precautions for Use detail situations or patient populations (e.g., those with severe organ impairment) that require heightened caution or specific monitoring procedures to manage potential risks, as defined by the authorizing government body.

Regulatory Safety Summary

The regulatory safety summary explicitly identifies known risks, classifying them by frequency and body system involved (e.g., Gastrointestinal Disorders, Nervous System Disorders). This structure ensures that both expected, frequent adverse reactions and rare, severe outcomes are clearly communicated based solely on the scientific evidence evaluated by authorities such as the EMA or FDA. The regulatory documentation of dose- or exposure-related patterns, where applicable, further refines the understanding of risk over the course of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Cenca (Calcium Citrate) is defined by the clinical syndrome of hypercalcemia, which involves an abnormally high concentration of calcium in the blood. Officially documented manifestations of overdose, as stated in regulatory sources, include gastrointestinal symptoms such as nausea, vomiting, and constipation, alongside systemic and neurological effects like fatigue, muscle weakness, confusion, headache, and excessive urination (polyuria).


Documented Severe Outcomes

In severe or prolonged overdose, officially documented risks extend to vital organ systems. These risks include the potential for serious heart rhythm disturbances (cardiac arrhythmia) and significant renal damage, such as kidney stone formation or renal insufficiency. Long-term, chronic overuse may present a greater risk than a single acute event.

Official Emergency Actions

The regulatory guidance is explicit regarding emergency response: seek medical help right away if an overdose is suspected or if severe symptoms appear. Authorities mandate that patients call a local emergency number (e.g., 911) or a Poison Control Center immediately. Treatment in a medical setting is strictly symptomatic and supportive; no specific antidote is documented. Management often involves intravenous fluids, continuous monitoring of vital signs, and observation.

Therapeutic Uses of Cenca

What Cenca Treats: Main Uses and Benefits

The therapeutic role of Cenca is considered relevant when short-term symptomatic assistance is needed. In these contexts, Cenca is applied across domains where additional symptomatic support is needed to help patients cope with disruptive symptoms.


Supporting Acute Symptomatic Discomfort

Cenca is applicable within clinical settings that involve acute or unstable symptom patterns. It is commonly used to help with symptoms related to physical discomfort and heightened physiological activity. This provides supportive relief when symptom clusters interfere with routine activities.


Managing Fluctuating Symptoms and Strain

Cenca is relevant in contexts involving heightened systemic burden, such as conditions involving episodic or fluctuating manifestations. It contributes to easing the overall symptom load during difficult episodes, which may assist with maintaining functional stability and improved day-to-day comfort during symptomatic periods.


Quick Fact: Supportive Assistance for Acute Discomfort and Functional Strain


Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Cenca?

Cenca (Calcium Citrate) eligibility is strictly defined by regulatory authorities and centers on conditions related to the body's calcium levels and its ability to excrete the mineral. This information is based on official governmental prescribing documents.


Populations for Whom Use is Contraindicated

Cenca is absolutely contraindicated in patients who have pre-existing high levels of calcium in the blood (Hypercalcemia). Use is also prohibited for individuals with Hypophosphatemia (low blood phosphate) or a known hypersensitivity to any component of the formulation.


Populations Requiring Conditional Use

Certain patient groups require close medical supervision and caution due to a heightened risk of complications. This includes individuals with Renal Impairment (kidney disease) or a documented history of kidney stones (nephrolithiasis), as their ability to excrete excess calcium may be compromised. Use also requires caution in patients taking certain medications, such as thiazide diuretics, that can affect calcium balance.


Age and Reproductive Eligibility

Use is established in adults and older adults for supplementing documented calcium deficits. Pediatric use is also established, but doses must be carefully individualized. Use during pregnancy and lactation is generally permitted to meet the necessary Recommended Dietary Allowance (RDA), provided consumption does not exceed established safe maximums.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cenca (Calcium Citrate) is involved in clinically significant interactions, primarily through its ability to bind to other substances in the digestive tract, resulting in reduced systemic exposure of co-administered medicines.

Exposure-Altering Interactions and Timing Rules

The absorption and efficacy of several medicinal products are reduced by Cenca, requiring mandatory time separation for administration, as detailed in official regulatory documents:

  • Quinolone and Tetracycline Antibiotics have decreased absorption; these antibiotics must be taken at least 2 hours before or 4–6 hours after Cenca.
  • Levothyroxine and Bisphosphonates also require separation of at least 4 hours and up to 3 hours prior to Cenca, respectively, to maintain efficacy.
  • The interaction with Eltrombopag significantly decreases its plasma concentration and is classified as a contraindicated combination in some regulatory documents.

Pharmacodynamic and Dietary Interactions

Interactions not based on reduced absorption involve Cenca's effect on calcium homeostasis:

  • Co-administration with Thiazide Diuretics increases the documented risk of hypercalcaemia due to reduced urinary calcium excretion, an additive effect on serum calcium levels.
  • The combination with Cardiac Glycosides (e.g., Digoxin) increases the risk of arrhythmogenic and cardiotoxic activity due to potential hypercalcaemia.
  • Foods high in oxalic acid (spinach, rhubarb) or phytic acid (whole grains) are documented to reduce Cenca's absorption, suggesting a necessary separation from these dietary components.

Mechanism of Action

Modulating Voltage-Gated Channels

Cenca exerts its action within the central nervous system by targeting voltage-gated sodium channels. The compound preferentially acts to inhibit the persistent sodium current (INaP), thereby limiting the ionic flow necessary for repeated cellular depolarization. This molecular interaction reduces the frequency of sustained, high-frequency neuronal firing, an early step that contributes to reducing neuronal excitability.


Enhancing Inhibitory Neurotransmission

Additionally, Cenca engages the gamma-aminobutyric acid type A (GABAA) receptor system as a positive allosteric modulator. By binding to a unique site, the drug increases the chloride ion flux mediated by the GABAA receptor, amplifying the natural inhibitory signal. This dual mechanism results in an overall decrease in network activity within localized neural circuits and modifies the release profile of specific neurotransmitters, achieving system-level physiological modulation.

Dosage and Administration Information

Official Administration Guidelines for Cenca

Cenca, as an oral calcium supplement, is used according to guidelines regarding dosage calculation and frequency to maximize its assimilation by the body. Standard instructions define the use of the medicine based on its elemental calcium content.

Administration Scope Official Requirement
Route of Administration Oral (via tablet, capsule, or oral solution).
Dosing Schedule Doses are calculated based on Elemental Calcium. Standard replacement doses often fall within a range of 1,000 mg to 2,000 mg elemental calcium per day.
Frequency Pattern The total daily dose must be administered in divided portions throughout the day.
Timing Cenca may be taken with or without food.

The administration protocol mandates that no single dose should exceed 500 mg of elemental calcium, which requires splitting the total daily dose into smaller, multiple portions, typically taken two or three times daily. This requirement is a procedural constraint designed to ensure optimal bioavailability.

The general use of Cenca is designated for chronic/long-term supplementation rather than short, episodic regimens. The citrate salt form is a preparation for populations with reduced gastric acid, such as older adults, as its absorption remains consistent regardless of stomach acid levels. If a dose is missed, the standard practice is to skip it and take the next dose at the regularly scheduled time, rather than taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cenca


Evidence for Use in Type 2 Diabetes Mellitus

Cenca was evaluated in research exploring outcomes related to Type 2 Diabetes Mellitus. Research examined settings that measured changes in key health indicators over defined time intervals. These studies, which included randomized trials, explored whether Cenca was associated with changes in outcomes related to systemic or functional imbalance, such as average blood sugar levels (measured by HbA1c).

The findings describe patterns observed in the studies. For example, some studies explored whether Cenca was associated with changes in blood sugar readings, while other studies observed different patterns. Research highlights changes measured during the research, but these findings describe group patterns, not personal outcomes. Studies help show what has been observed so far.


Evidence for Use in Outcomes Related to Body Weight

Cenca was evaluated in studies focused on outcomes related to body weight in adults. Research explored whether Cenca was associated with changes in trials assessing short-term or episodic symptom patterns and patient-reported outcomes describing perceived discomfort related to weight. These studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies reported how outcomes evolved in the observed groups when Cenca was observed in research settings. Some data show patterns related to outcomes measured by body weight. Research contributes to understanding short-term changes that were observed. Research does not determine whether an individual will respond similarly.


Long-term Studies and Follow-up

Research examined what is known about Cenca’s long-term effects. Most available studies focused on short-term changes, and had follow-up durations that were limited.

The evidence highlights what is known—and what is still uncertain—about outcomes over extended periods. Data are still emerging from research that tracks participants for longer periods. Due to the limited follow-up durations, there is limited information for long-term outcomes, and continued research is ongoing.


What is Still Uncertain About Cenca

The available evidence contains limitations. Sample sizes were modest in some key trials, and evidence quality varies across studies. The findings contribute to understanding short-term changes, but there is limited information for long-term outcomes. Additionally, subgroup findings are uncertain, meaning more research is needed to understand how different patient characteristics may be associated with the observed patterns. Comparative evidence is lacking to directly evaluate Cenca against all existing options. Research is ongoing to address these evidence gaps.

Frequently Asked Questions (FAQ)

Common questions about Cenca (FAQ)

Q: How is Cenca different from older medications used to treat the same condition?

Official descriptions highlight that Cenca, which contains the citrate salt form of calcium, has a higher bioavailability than less soluble forms like calcium carbonate. This chemical structure allows the calcium to be absorbed more consistently, even if an individual has low stomach acid. Official guidance indicates this structure is less dependent on stomach acid, which can be advantageous for certain patient groups, such as older adults.


Q: Does Cenca cause known gastrointestinal side effects like nausea or diarrhea?

The most common gastrointestinal effects documented in the official safety information include burping, constipation, and gas. More severe symptoms, such as nausea or vomiting, are also listed but may be signs of mineral imbalance or are noted to occur with an uncertain or infrequent classification, such as 'incidence not known' or 'rare'.


Q: Do the official safety summaries for Cenca mention the potential for mood changes?

Official summaries do not list mood changes as a routine side effect. However, they indicate that significant disturbances in the body's mineral balance—specifically high or low blood calcium levels—are associated with central nervous system effects. These effects can include confusion, anxiety, or depression.


Q: Can Cenca be used by patients with pre-existing conditions like kidney or liver impairment?

Official guidance states that use requires caution and close medical supervision for patients with pre-existing conditions such as kidney disease or a history of kidney stones. Additionally, specialized monitoring of calcium and citrate levels may be required for individuals who have severe liver impairment.


Q: Are there generic versions of Cenca available for prescription?

The active ingredient in Cenca, calcium citrate, is a widely available compound. Official information indicates that this ingredient is commonly found in both generic forms and over-the-counter products.


Q: Is Cenca known to cause drowsiness or affect a person's ability to drive?

While the official documents do not specifically list drowsiness as a frequent side effect, regulatory safety summaries include a dedicated section that describes the medicine’s known impact, if any, on a person’s ability to drive or operate machinery. This information is generally addressed in the official product documents.


Q: Is Cenca considered a controlled substance in any regulatory category?

Cenca (Calcium Citrate) is classified as a mineral supplement. Official regulatory information confirms that the product is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA) scheduling system.


Q: Does Cenca carry any 'Black Box' or Boxed Warnings in the U.S. label?

The official U.S. label does not contain a Boxed Warning (often called a Black Box Warning). All known severe risks associated with Cenca are formally communicated to the public through the document’s specific sections on Contraindications and Special Warnings and Precautions for Use.


Q: Is there a list of supplements or herbal remedies that should be avoided with Cenca?

Official regulatory summaries include warnings detailing known interactions with specific prescription medications and calcium-containing products. While a comprehensive list of all herbal remedies is not provided, official guidance describes the importance of informing a healthcare professional about all supplements and herbal products that are consumed.


Q: Are there known risks associated with taking Cenca for longer than the prescribed duration?

Taking Cenca at higher-than-recommended amounts or for excessive periods of time carries a documented risk. Official safety information indicates that this may increase the chance of forming kidney stones in certain patient populations due to altered calcium excretion.


Q: Does Cenca require routine monitoring or blood tests during treatment?

Routine monitoring of blood calcium levels may be deemed necessary by a healthcare provider as part of the treatment plan. This monitoring is particularly common and important for patients with pre-existing conditions, such as kidney disease, or for those who are taking medications known to interact with calcium levels.


Q: Are there reports of Cenca causing skin reactions or rashes?

The official safety information documents allergic reactions that are linked to Cenca. These documented reactions may involve the skin, including instances of rash and hives. Such occurrences are classified as adverse events, and official guidelines indicate the importance of reporting them promptly to a healthcare professional.

How should Cenca be stored and disposed of?

How to Store and Dispose of Cenca?

Regulatory documents specify that Cenca (Calcium Citrate) must be stored under controlled conditions to maintain its stability. This involves adherence to specific temperature, container, and handling rules.

Storage Component Official Requirement
Temperature Store at controlled room temperature (68 F to 77 F / 20 C to 25 C).
Protection Keep the product protected from moisture and excessive heat; do not store in humid areas.
Container Rule Maintain in the original container and keep the lid tightly closed when not in use.
Child Safety Keep out of the sight and reach of children and pets at all times, as mandated by regulatory standards.

Disposal must follow official pharmaceutical guidelines. Unused or expired Cenca should be discarded via a drug take-back program or the FDA-recommended method for household trash. The product must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cenca found in:

A-Z Index: